Share on StockTwits

Charles River Laboratories (NYSE:CRL) VP Nancy Gillett sold 4,000 shares of Charles River Laboratories stock on the open market in a transaction dated Thursday, February 20th. The stock was sold at an average price of $58.96, for a total value of $235,840.00. Following the transaction, the vice president now directly owns 50,510 shares of the company’s stock, valued at approximately $2,978,070. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

A number of analysts have recently weighed in on CRL shares. Analysts at Ned Davis Research upgraded shares of Charles River Laboratories from a “neutral” rating to a “buy” rating in a research note on Tuesday, February 18th. Separately, analysts at Citigroup Inc. initiated coverage on shares of Charles River Laboratories in a research note on Tuesday, February 18th. They set a “neutral” rating on the stock. Finally, analysts at Barclays raised their price target on shares of Charles River Laboratories from $41.00 to $55.00 in a research note on Thursday, February 13th. They now have an “equal weight” rating on the stock. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the company. Charles River Laboratories has an average rating of “Hold” and an average price target of $52.13.

Shares of Charles River Laboratories (NYSE:CRL) traded down 0.08% during mid-day trading on Monday, hitting $59.10. The stock had a trading volume of 137,833 shares. Charles River Laboratories has a 52-week low of $39.25 and a 52-week high of $59.95. The stock has a 50-day moving average of $57.35 and a 200-day moving average of $51.08. The company has a market cap of $2.787 billion and a P/E ratio of 27.85.

Charles River Laboratories (NYSE:CRL) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.05. The company had revenue of $289.20 million for the quarter, compared to the consensus estimate of $289.56 million. During the same quarter in the previous year, the company posted $0.64 earnings per share. The company’s revenue for the quarter was up 3.2% on a year-over-year basis. On average, analysts predict that Charles River Laboratories will post $3.08 earnings per share for the current fiscal year.

Charles River Laboratories International, Inc is a global provider of solutions, which accelerate the early-stage drug discovery and development process.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.